Tony Chou

Dr. Chou has over 25 years of healthcare experience as both an academic interventional cardiologist and medical device industry executive. He completed his cardiology and interventional cardiology training at UCSF and previously served as Director of the Adult Cardiac Catheterization Laboratories at UCSF Moffitt-Long Hospitals as a fulltime faculty member. His industry experience started as part of the corporate/business development team at Abbott Laboratories, and he transitioned to various positions in general management and business development in the business unit which became known as Abbott Vascular. As Division Vice President and General Manager of Vascular Closure, he oversaw the development, manufacturing, clinical trials, FDA PMAS/PMA, international regulatory registration and global launches of the femoral closure devices Perclose ProGlide and StarClose SE. Dr. Chou became a General Partner of the healthcare- focused venture capital firm The Vertical Group in 2006. In that capacity, he is or has served as director or advisor to the boards of Silk Road Medical (IPO), Outset Medical (IPO), Singular Bio (acquired by Invitae), Atheromed (acquired by Volcano), Accriva/Accumetrics (acquired by Werthen), Lutonix (acquired by CR Bard), Omada Health and other privately held companies. Dr. Chou was a founder and served as initial CEO of Silk Road Medical.